LL-37 5mg
LL-37 is an antimicrobial cathelicidin peptide investigated in laboratory research for immune modulation, tissue repair, and pathogen defense.
Mechanism
Disrupts target cell membranes via an amphipathic alpha-helical conformation while neutralizing bacterial endotoxins and modulating innate inflammatory signaling pathways.
Dosing
Preclinical documentation describes an initial experimental starting point of 100 mcg administered once daily.
Reconstitution
Reconstituting a 5 mg vial with 3.0 mL of bacteriostatic water yields an approximate working concentration of 1.67 mg/mL (16.7 mcg per U-100 unit).
Storage
Store the unmixed lyophilized powder at -20 °C, and maintain the reconstituted liquid refrigerated at 2–8 °C protected from light without freezing.
Mix & measure LL-37 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure LL-37 5mg
Vial strength → BAC water → target dose
Total doses in vial: 50.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (1× daily) | 6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg (1× daily) | 9 units (0.09 mL) |
| Weeks 5–6 | 200 mcg (1× daily) | 12 units (0.12 mL) |
| Weeks 7–12 | 250 mcg (1× daily) | 15 units (0.15 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- 2
Release it slowly down the vial's inner wall to limit foaming.
- 3
Swirl or roll gently until fully dissolved — don't shake.
- 4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Supplies Needed
Peptide Vial
Lyophilized LL-37 vial containing 5 mg of active research compound.
Insulin Syringes (U-100)
1 mL syringes for precise measurement of microgram-level liquid doses.
Bacteriostatic Water
Diluent used to reconstitute 3.0 mL per 5 mg vial.
Alcohol Swabs
Antiseptic pads for cleaning the rubber stopper and injection site before each draw.
Why researchers study it
Antimicrobial host defense
Wound healing & tissue repair
Immune modulation
Skin inflammation
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
LL-37 is a biologically active, cationic host-defense peptide containing 37 amino acids, derived via proteolytic cleavage from the human precursor protein hCAP-18. Primarily synthesized by circulating neutrophils and barrier epithelial surfaces, it represents the sole functional cathelicidin identified in human physiology. In preclinical settings, this amphipathic alpha-helical molecule demonstrates extensive antimicrobial properties by interacting directly with pathogen membrane structures to cause permeabilization. Beyond basic microbial inhibition, researchers actively investigate LL-37 for its regulatory impact on mammalian tissue microenvironments. Preclinical cell cultures and animal models indicate that it participates in wound re-epithelialization, induces cellular migration, and stimulates neo-vascularization via endothelial cell signaling. Concurrently, it displays immunomodulatory actions such as binding to and neutralizing bacterial lipopolysaccharides, which alters downstream inflammatory cascades. Despite widespread scientific interest in its biochemical mechanisms, LL-37 is an unapproved experimental compound designated strictly for in vitro and laboratory research. Validated clinical dosing frameworks for systemic human administration do not exist, and existing clinical literature remains confined to localized topical applications or intratumoral oncological evaluations. Consequently, published subcutaneous schedules represent theoretical dilution models designed strictly for laboratory consistency.
References
- 1.PubMed, 2025 — LL-37 structure, processing from hCAP-18, and host-defense functions
- 2.PubMed, 2025 — Amphipathic structure and membrane-disrupting antimicrobial mechanism of cathelicidin LL-37
- 3.PubMed, 2025 — LL-37 immunomodulation: LPS neutralization and modulation of inflammatory responses
- 4.ClinicalTrials.gov, 2025 — LL-37 / cathelicidin clinical study registry: topical and intralesional evaluations
- 5.PubMed, 2025 — LL-37 promotes re-epithelialization and wound healing in skin models
- 6.PubMed, 2025 — LL-37 promotes angiogenesis via endothelial activation in preclinical work
- 7.PubMed, 2025 — Phase I intratumoral LL-37 in melanoma: immune activation and dermatologic toxicity
- 8.PubMed, 2025 — LL-37 limitations: mammalian-cell cytotoxicity, serum inhibition, and proteolytic stability
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allTestoluten 20mg
An oral animal-derived testicular peptide extract explored in bioregulator research for male endocrine and reproductive support.
View ProtocolLarazotide 5mg
An oral, gut-restricted octapeptide tight-junction regulator researched for paracellular barrier permeability and celiac disease models.
View ProtocolACE-031 1mg
Investigational ActRIIB-Fc decoy protein evaluated for myostatin inhibition, discontinued due to vascular adverse events.
View Protocol